Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:ECOR NASDAQ:HIND NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.95+3.0%$10.50$7.19▼$14.76$48.67M0.296,897 shs21,775 shsECORelectroCore$6.41+2.2%$6.58$4.16▼$8.64$52.01M0.6850,154 shs71,004 shsHINDVyome$2.06-1.9%$2.38$1.75▼$33.16$14.74M1.3823,450 shs19,881 shsNSPRInspireMD$1.15-0.9%$1.51$1.02▼$2.93$53.93M0.82174,764 shs261,553 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%-11.74%+6.12%-22.06%+28.85%ECORelectroCore0.00%-3.69%+0.97%+15.05%-7.93%HINDVyome0.00%+3.45%-1.41%-23.36%+209,999,900.00%NSPRInspireMD0.00%-1.69%-15.33%-33.33%-54.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.95+3.0%$10.50$7.19▼$14.76$48.67M0.296,897 shs21,775 shsECORelectroCore$6.41+2.2%$6.58$4.16▼$8.64$52.01M0.6850,154 shs71,004 shsHINDVyome$2.06-1.9%$2.38$1.75▼$33.16$14.74M1.3823,450 shs19,881 shsNSPRInspireMD$1.15-0.9%$1.51$1.02▼$2.93$53.93M0.82174,764 shs261,553 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%-11.74%+6.12%-22.06%+28.85%ECORelectroCore0.00%-3.69%+0.97%+15.05%-7.93%HINDVyome0.00%+3.45%-1.41%-23.36%+209,999,900.00%NSPRInspireMD0.00%-1.69%-15.33%-33.33%-54.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate BuyN/AN/AECORelectroCore 2.00Hold$18.00180.81% UpsideHINDVyome 2.40Hold$15.00628.16% UpsideNSPRInspireMD 3.00Buy$4.50291.30% UpsideCurrent Analyst Ratings BreakdownLatest HIND, ECOR, DXR, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026HINDVyome Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/4/2026HINDVyome Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026HINDVyome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)3/27/2026DXRDaxor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/27/2026ECORelectroCore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ECORelectroCore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold2/24/2026NSPRInspireMD Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.002/24/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy2/11/2026DXRDaxor Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxor$10.30M4.87N/AN/AN/A∞ECORelectroCore$32.03M1.66N/AN/A($0.69) per share-9.29HINDVyome$320K45.19N/AN/A$0.67 per share3.07NSPRInspireMD$10.85M4.97N/AN/A$1.83 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AN/AECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%N/AHINDVyome-$10.26M-$125.20N/AN/AN/A-270.58%-279.99%-142.04%N/ANSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest HIND, ECOR, DXR, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million3/19/2026Q4 2025ECORelectroCore-$0.35-$0.34+$0.01-$0.34$9.09 million$9.24 million3/2/2026Q2 2025DXRDaxorN/A-$0.1010N/A-$0.1010N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxor$0.030.30%N/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/AHINDVyomeN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AECORelectroCoreN/A1.021.24HINDVyomeN/A1.991.99NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%ECORelectroCore26.74%HINDVyome22.06%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%ECORelectroCore13.80%HINDVyome33.00%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor375.04 million2.04 millionNot OptionableECORelectroCore508.30 million6.97 millionNot OptionableHINDVyome507.02 million4.70 millionN/ANSPRInspireMD5046.89 million18.33 millionOptionableHIND, ECOR, DXR, and NSPR HeadlinesRecent News About These CompaniesScott Ward Buys 15,995 Shares of InspireMD (NYSE:NSPR) Stock3 hours ago | insidertrades.comInsider Buying: InspireMD (NYSE:NSPR) Director Acquires 15,995 Shares of StockMay 8 at 7:26 PM | marketbeat.comInsider Buying: InspireMD (NYSE:NSPR) Director Acquires 73,255 Shares of StockMay 8 at 7:10 PM | marketbeat.comGary Roubin Buys 90,000 Shares of InspireMD (NYSE:NSPR) StockMay 8 at 5:19 PM | marketbeat.comInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare ConferenceMay 6 at 4:05 PM | globenewswire.comInspireMD Inc.: InspireMD Reports First Quarter 2026 Financial ResultsMay 5, 2026 | finanznachrichten.deInspireMD (NSPR) Q4 2025 Earnings TranscriptMay 5, 2026 | fool.comInspireMD, Inc. (NSPR) Q1 2026 Earnings Call TranscriptMay 4, 2026 | seekingalpha.comInspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2026 | zacks.comInspireMD Reports First Quarter 2026 Financial ResultsMay 4, 2026 | globenewswire.comInspireMD recalls CGuard Prime 135 cm stent delivery system in US, gets nod to study neuroprotection techMay 2, 2026 | massdevice.comNSPR rallies after hours on FDA green light for key stroke-prevention trial despite withdrawn annual guidanceMay 2, 2026 | msn.comInspireMD Recalls CGuard Prime Delivery System, Pauses U.S. LaunchMay 1, 2026 | tipranks.comInspireMD Receives FDA Approval for CGUARDIANS III Pivotal Study of SwitchGuard Neuro Protection SystemMay 1, 2026 | quiverquant.comQInspireMD Reports 53% Year-Over-Year Unit Sales Growth Amid Anticipated FDA Approvals and Voluntary Recall of CGuard Prime 135 cm Delivery SystemMay 1, 2026 | quiverquant.comQInspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection SystemMay 1, 2026 | globenewswire.comInspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery SystemMay 1, 2026 | globenewswire.comInspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?May 1, 2026 | marketbeat.comInspireMD to Announce First Quarter 2026 Financial ResultsApril 27, 2026 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)April 14, 2026 | prnewswire.comAfter Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)April 8, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026RPM International's Blowout Quarter Sparks a 15% Rally By Thomas Hughes | April 10, 2026East West Bancorp: Confronting the Risks With Record Results By Peter Frank | April 10, 2026JPMorgan Stock Is Coiling Near All-Time Highs — Here's What Comes NextBy Thomas Hughes | April 14, 2026HIND, ECOR, DXR, and NSPR Company DescriptionsDaxor NASDAQ:DXR$9.95 +0.29 (+3.00%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$10.24 +0.29 (+2.91%) As of 05/8/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.electroCore NASDAQ:ECOR$6.41 +0.14 (+2.23%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$6.41 0.00 (0.00%) As of 05/8/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Vyome NASDAQ:HIND$2.06 -0.04 (-1.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.15 +0.09 (+4.27%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.InspireMD NYSE:NSPR$1.15 -0.01 (-0.86%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.21 +0.06 (+5.04%) As of 05/8/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
